“New research by investigators at the University of California, San Francisco and the Children’s National Health System, has provided early evidence that liquid biopsy testing could help doctors monitor how well treatments are working in kids with diffuse midline gliomas.
“Brain cancers present a challenge for longitudinal monitoring, because obtaining repeat biopsy samples is dangerous and difficult. But liquid biopsy techniques have now opened the possibility of tracking these and other tumors over time based on analysis of tumor genetic material that is shed into the blood or other body fluids.”
Go to full article published by GenomeWeb on Oct 15, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.